Experimental Phage Therapy of Bacterial Infections

This study is currently recruiting participants.
Verified August 2013 by Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
Sponsor:
Information provided by:
Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
ClinicalTrials.gov Identifier:
NCT00945087
First received: July 21, 2009
Last updated: September 5, 2013
Last verified: August 2013
  Purpose

The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated.


Condition Intervention
Bacterial Infections
Other: Bacteriophage preparation

Study Type: Interventional
Official Title: Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections

Resource links provided by NLM:


Further study details as provided by Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences:

Study Start Date: December 2005
Intervention Details:
    Other: Bacteriophage preparation
    Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
    Other Name: Phage preparation, bacteriophage formulation
Detailed Description:

Bacterial infections of different tissues and organs that prove incurable by antibiotics are a serious clinical problem. Bacteriophages (phages) are bacterial viruses which attack, multiply within, and then destroy bacteria. They can efficiently destroy bacteria which have acquired resistance to antibiotics and which cause life-threatening infections. The method of treating bacterial infections using phages has been known since the beginning of the 20th century. This experimental treatment enables the use of phage preparations under the rules of a therapeutic experiment (on the basis of the respective Polish regulations) in cases where no effective available therapy exists or the use of the targeted drug is contraindicated. It is not a research study.

The bacteriophage preparations which are used in the treatment procedures contain phages from the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences in Wrocław. For each patient only specific formulations of single phage or a phage mixture that are active against the pathogenic bacterial strain or strains isolated from the patient are used for the treatment.The isolation of live bacterial pathogen from the patient is necessary to carry out a phage-typing procedure to determine if the preparation of an active formulation is possible which is a prerequisite for receiving the treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or over.
  • Men and women of reproductive age must use contraception during and one month after the therapy. Women of reproductive age must have negative result of a pregnancy test before beginning of the treatment.
  • Signed informed consent.
  • Antibiotic therapy-resistant, chronic, symptomatic bacterial infection of the skin, subcutaneous tissue, bone, bone marrow, joints, fistulas, wounds, bedsores, genital and/or urinary tract, digestive tract, middle ear, sinuses, tonsils, upper and lower respiratory tract, or a state in which a targeted antibiotic therapy is impossible to carry out due to other medical reasons.
  • A putative pathogenic bacteria such as Staphylococcus, Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella, Salmonella, Serratia, Proteus, Pseudomonas, Stenotrophomonas, Acinetobacter, Burkholderia, or Morganella present in the site of the said infection as confirmed by the result of microbiological culture.
  • Ineffective antibiotic therapy of said infection and/or antibiogram-confirmed multidrug resistance of a putative pathogenic bacteria such as Staphylococcus, Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella, Salmonella, Serratia, Proteus, Pseudomonas, Stenotrophomonas, Acinetobacter, Burkholderia, or Morganella.
  • The presence in the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences of a phage able to lyse a bacterial strain cultured from a patient in the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences (positive result of a phage-typing procedure).

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Malabsorption syndrome, allergy to food or animal protein, or advanced hepatic insufficiency when it is impossible to apply the phage preparation using other route than oral.
  • Allergy to components of phage preparations.
  • A health condition which does not allow conducting the experimental therapy in the opinion of the qualifying physician.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00945087

Contacts
Contact: Andrzej Górski, M.D. Ph.D. +48 71-3709905 agorski@ikp.pl
Contact: Ryszard Międzybrodzki, M.D. Ph.D. +48 71-3709901 cm@iitd.pan.wroc.pl

Locations
Poland
Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences Recruiting
Wrocław, Poland, 53-114
Principal Investigator: Andrzej Górski, M.D. Ph.D.         
Sub-Investigator: Ryszard Międzybrodzki, M.D. Ph.D.         
Sub-Investigator: Wojciech Fortuna, M.D. Ph.D.         
Sub-Investigator: Krzysztof Szufnarowski, M.D.         
Sub-Investigator: Sławomir Letkiewicz, M.D. Ph.D.         
Sub-Investigator: Beata Weber-Dąbrowska, Ph.D.         
Sub-Investigator: Paweł Rogóż, M.D.         
Sponsors and Collaborators
Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
Investigators
Study Director: Andrzej Górski, M.D. Ph.D. Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00945087     History of Changes
Other Study ID Numbers: OTF-1
Study First Received: July 21, 2009
Last Updated: September 5, 2013
Health Authority: Poland: Ethics Committee

Keywords provided by Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences:
bacteriophage
bacteriophage preparation
bacterial infection
antibiotic-resistant infection
multidrug-resistant bacteria
MRSA

Additional relevant MeSH terms:
Bacterial Infections

ClinicalTrials.gov processed this record on April 22, 2014